Vancouver, British Columbia – May 01, 2024 – HYTN Innovations Inc. (CSE: HYTN “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds including cannabis, applauds the recent formal recommendation by the U.S. Justice Department, endorsed by the Drug Enforcement Agency (DEA), to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This historic shift, pending review by the White House Office of Management and Budget (OMB), recognizes the medical utility of cannabis and its lower ...
[ more ]
